問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Dermatology

Taipei Medical University Hospital (在職)

Division of Dermatology

更新時間：2023-09-19

李婉若Lee, Woan-Ruoh
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

28Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李婉若

List

46Cases

2025-03-01 - 2027-12-31

Phase III

Active
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of dupilumab for the treatment of pruritus of Lichen Simplex Chronicus (LSC) in adults

  • Condition/Disease

    Lichen Simplex Chronicus (LSC)

  • Test Drug

    injection

Participate Sites
3Sites

Recruiting3Sites

2024-09-15 - 2026-12-31

Phase III

Active
Master protocol of two randomized, double blind, placebo-controlled, multi-center, parallel group studies to evaluate the efficacy and safety of dupilumab in adult patients with chronic pruritus of unknown origin (CPUO)

  • Condition/Disease

    chronic pruritus of unknown origin (CPUO)

  • Test Drug

    injection

Participate Sites
4Sites

Recruiting4Sites

2023-04-01 - 2028-12-31

Phase II

Active
An Open-Label multinational, multicenter study to evaluate the long-term safety, tolerability and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate to severe atopic dermatitis

  • Condition/Disease

    moderate to severe atopic dermatitis

  • Test Drug

    injective

Participate Sites
7Sites

Recruiting7Sites

2021-09-01 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-09-01 - 2023-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2025-10-01 - 2028-04-30

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-01-09 - 2026-02-28

Phase III

Completed
A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA

  • Condition/Disease

    Alopecia Areata

  • Test Drug

    PF-06651600

Participate Sites
6Sites

Recruiting6Sites

2020-10-09 - 2020-12-10

Phase III

Completed
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF CRISABOROLE OINTMENT, 2% IN CHINESE AND JAPANESE PEDIATRIC AND ADULT SUBJECTS (AGES 2 YEARS AND OLDER) WITH MILD TO MODERATE ATOPIC DERMATITIS

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    Crisaborole

Participate Sites
7Sites

Terminated7Sites

2018-11-15 - 2020-12-31

Phase III

Completed
A Phase 3 Randomized Withdrawal, Double Blind, Placebo Controlled, Multi Center Study Investigating the Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over, with Moderate to Severe Atopic Dermatitis with the Option of Rescue Treatment in Flaring Subjects

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    PF-04965842

Participate Sites
6Sites

Terminated6Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2020-06-01 - 2021-06-16

Phase III

Completed
A PHASE 3B RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE CONTROLLED MULTI-CENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS

  • Condition/Disease

    MODERATE TO SEVERE ATOPIC DERMATITIS

  • Test Drug

    PF-04965842(Abrocitinib)Dupixent

Participate Sites
6Sites

Terminated6Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB